This study is a randomized controlled clinical trial of triple-blind, parallel group, which will be carried out for 8 weeks for assessing antioxidant level, inflammatory markers and cardio-metabolic risk factors. Inclusion criteria were the age range of 10-18, no special diet for at least 2 months, no taking of NSAIDS (Ibuprofen, Aspirin, Warfarin, etc.) and thyroid, drugs that reduce appetite and decrease fat and blood sugar, the use of hormone therapy, sedatives, antidepressants and anticoagulants. subjects can leave the study in the absence of consent at any stage of the study. Exclusion criteria included lack of proper use of drugs or placebo, people who are allergic to fish and any seafood and fish oil as well as taking anticoagulants and people with hemophilia.They were randomly assigned to one of two groups receiving the supplement and placebo. A 500 mg soft gel AstaShrymp oil for intervention and placebo for the control group will be administered for 8 weeks. One capsule will use a day after breakfast . For those who are enrolled, the demographic questionnaire was completed. To ensure the stability of dietary intakes, a 24-hour dietary recall will be taken at the beginning and at the end of the study. Data on physical activity will be achieved through questionnaires.